Cancer Research
Cancer Research
Survivorship & ManagementOctober 08-09
Noscow, Russia

Cancer Survivorship 2018

www.cancer.euroscicon.com

Day 1, Agenda

General Session

08:00 AM	INTRODUCTION		
09:00 AM	PLENARY		
10:00 AM	KEYNOTE		
	Networking & Refreshments Break @ Foyer		
11:00 ANA	HALL 01	HALL 02	HALL 03
	Talks On: Cancer Survivorship	Talks On: Chronic Cancer Survivors	Talks On: Adolescents Survivors
	Talks On: Oncology Survivors	Talks On: Liver Cancer Survivors	Talks On: Breast Cancer Survivors
	SESSION DISCUSSION	SESSION DISCUSSION	SESSION DISCUSSION
02:00 PM	Panel Over:	Panel Over:	Panel Over:
	Oncology	Chemotherapy	Stem Cell Therapy
	Workshop On:	Workshop On:	Workshop On:
	Cytotoxic Agents of Oncology	Treatments Of Chemotherapy	Treatment of Stem Cell Therapy
	Lunch Break @ Restaurant	Lunch Break @ Restaurant	Lunch Break @ Restaurant
04:00 PM	Talks On:	Talks On:	Talks On:
	Oncogenomics	Oncogenes Mutation Strategies	Oncology Screening & Stagging
	Lectures on:	Lectures on:	Lectures on:
	Malignancy Aggravation	Cancer Cirrhosis	Hormonal Therapy
06:00 PM	Session On:	Session On:	Session On:
	Research On Cancer Screening	Functional Research On Oncogenomics	Research Analysis of Cancer
	NETWORKING	NETWORKING	NETWORKING

Day 2, Agenda

General Session

08:00 AM	INTRODUCTION		
09:00 AM			
09.00 Alvi	PLENARY		
10:00 AM	KEYNOTE		
	Networking & Refreshments Break @ Foyer		P
	HALL 01	HALL 02	HALL 03
11:00 AM	Talks On:	Talks On:	Talks On:
	Cancer	Innovations of Cancer Diagnosis	Melanoma
	Talks On:	Talks On:	Talks On:
	Biopsy	Sensitile Lymph node	Surgical Biopsy
	SESSION DISCUSSION	SESSION DISCUSSION	SESSION DISCUSSION
	Panel Over:	Panel Over:	Panel Over:
02:00 PM	Parler Over.	Parler Over.	Pallel Over.
UZ:UU PIVI	Cancer Stagging Condition	Cancer Therapies	Immunotherapies
UZ.UU PIM	Cancer Stagging Condition	Cancer Therapies	Immunotherapies
U2.00 PM	Cancer Stagging Condition	Cancer Therapies Workshop On:	Immunotherapies
02.00 PM	Cancer Stagging Condition	Cancer Therapies	Immunotherapies
U2.UU PM	Cancer Stagging Condition	Cancer Therapies Workshop On:	Immunotherapies Workshop On: Innovations in
02:00 PM	Cancer Stagging Condition Workshop On: Cancer treatment	Cancer Therapies Workshop On: Targeted Therapies	Immunotherapies Workshop On: Innovations in Immunotherapies
	Cancer Stagging Condition Workshop On: Cancer treatment Lunch Break @ Restaurant	Cancer Therapies Workshop On: Targeted Therapies Lunch Break @ Restaurant	Immunotherapies Workshop On: Innovations in Immunotherapies Lunch Break @ Restaurant
	Cancer Stagging Condition Workshop On: Cancer treatment Lunch Break @ Restaurant Talks On:	Cancer Therapies Workshop On: Targeted Therapies Lunch Break @ Restaurant Talks On:	Immunotherapies Workshop On: Innovations in Immunotherapies Lunch Break @ Restaurant Talks On: Emerging Personalized
	Cancer Stagging Condition Workshop On: Cancer treatment Lunch Break @ Restaurant Talks On: Clinical DNA Sequencing	Cancer Therapies Workshop On: Targeted Therapies Lunch Break @ Restaurant Talks On: Bone Marrow Transplantation Lectures on: Haredity Concer Syndrome	Immunotherapies Workshop On: Innovations in Immunotherapies <i>Lunch Break @ Restaurant</i> Talks On: Emerging Personalized Medicine
	Cancer Stagging Condition Workshop On: Cancer treatment Lunch Break @ Restaurant Talks On: Clinical DNA Sequencing	Cancer Therapies Workshop On: Targeted Therapies Lunch Break @ Restaurant Talks On: Bone Marrow Transplantation Lectures on: Lunch Compare Survivormed	Immunotherapies Workshop On: Innovations in Immunotherapies <i>Lunch Break @ Restaurant</i> Talks On: Emerging Personalized Medicine Lectures on: Central Nervous System
04:00 PM	Cancer Stagging Condition Workshop On: Cancer treatment Lunch Break @ Restaurant Talks On: Clinical DNA Sequencing Lectures on: Molecular Oncology	Cancer Therapies Workshop On: Targeted Therapies Lunch Break @ Restaurant Talks On: Bone Marrow Transplantation Lectures on: Heredity Cancer Syndrome	Immunotherapies Workshop On: Innovations in Immunotherapies <i>Lunch Break @ Restaurant</i> Talks On: Emerging Personalized Medicine Lectures on: Central Nervous System Tumors

http://cancer.euroscicon.com/



4th Edition of World Congress on Cancer Research, Survivorship and Management

OCTOBER 08-09, 2018 MOSCOW, RUSSIA





Title: Bio Electron's Laser Acupuncture by KBTE Medical laser Device

Mr.Nick Kostovic, BIO TECHNOLOGICAL HEALTH CENTER INC. USA I am Italian and US citizen. I have strong Italian ties through my father, Ivo Kostovic who mother was Italian. Through his father roots he has and Asian origins. He was born on the island of Drvenik-Veli when it was part of region Dalmatia, Italy called Zirona. My mother Bosiljka Rodic Kostovic, with Russian roots, was born in city Omis also originally from Dalmatia region, of Italy. Dalmatia was part of Italy for many centuries and currently Dalmatia is located in Croatia Europe.

Title: KAPS-biomarker for early diagnosis of Prostate Cancer

Kailash Chadha, Roswell Park

Comprehensive Cancer Centre USA Kailash Chadha is the Emeritus Associate Member and Associate Professor of Oncology in the Department of Molecular and Cellular Biology at Roswell Park Cancer Institute, and in Department of Medicine, State University of New York at Buffalo, NY, USA. He got his Ph.D. degree in Virology from the University of Guelph, Guelph, Ontario, Canada. After his graduation he spent two years as a fellow of National Research Council of Canada

Title: In depth –omic analysis of tumor interstitial fluid of human breast: association with intrinsic tumor subtypes and clinical outcome

Irina Gromova Danish Cancer Society Research Centre Denmark Dr. Gromova is graduated from Moscow State University, Russia. She completed her PhD in Molecular Biology at the Institute of Gene Biology, Russian Academy of Science, Moscow. Soon after that, she was invited as a guest scientist to University of Aarhus, Department of Molecular Biology where she was working as Associate Professor until 2000. Since when she is working in Institute of Cancer Biology, Danish Cancer Society and her study is dedicated to understanding of breast cancer complexity aiming to develop and validate diagnostic, prognostic, and predictive biomarkers for clinical decision-making. She has published more than 90 papers in highly citied journals and is serving now as a leader of "Breast Cancer Biology" group. Bio<mark>graphy</mark>



Title: Altering Gut Microbiome to Enhance Therapeutic Efficacy in Resistant Colon Cancer by Natural Agents

Adhip P.N. Majumdar Wayne State University USA Dr. Adhip P.N. Majumdar, received his MS and Ph.D. degrees from the University of London, England, and D.Sc (Doctor of Science) degree in Gastroenterology from the University of Aarhus, Denmark. Dr. Majumdar has been a Professor at Wayne State University since 1992 and holds the post of Senior Research Career Scientist at the Detroit VA Medical Center. He has published over 200 original scientific articles and a multitude of book chapters/review articles. Dr.Majumdar's lab is particularly interested in elucidating the pathophysiology of age-related changes in the GI mucosa specifically those that lead to malignancy. To this end, Dr. Majumdar has been investigating the role of pluripotent, self-renewing CSCs in the development and progression of GI malignancies. Dr. Majumdar has been funded by the VA and NIH.

Title: Magnesium in Oncology: New Insights in a Forgotten Kation

Oliver Micke Franziskus Hospital Germeny Oliver Micke has completed his PhD at the age of 35 years from Muenster University Hospital in 2006. He is head of the Head of the department for radiotherapy and radiation oncology at the Franziskus Hospital Bielefeld since 2006. In addition he is the medical director of Franziskus Hospital Bielefeld, a premier teaching hospital of the Medical University of Hanover (MHH). He has published more than 200 papers in reputed national and international journals and has been serving as reviewer as well as an editorial board member of repute.

Title: Tripterygium Wilfordii Promotes Selective Cell Death via a Novel Na/K ATPase Pathway

Ioannis S. Patrikios European University of Cyprus Cyprus Professor Ioannis S. Patrikios received his BSc degree in Pre-Medical studies/Biochemistry from the City College of the City University of NY. He completed his PhD studies in 1994, specialized on Immunology and Lipids/Lipidomics and post-doctoral studies specialization in Medical Biochemistry at the City College of NY, next to the world-known Professor CS Russell. Professor Patrikios went through several different fellowships including research specializations /collaborations with different high reputation institutions including, Mount Sinai NY and was awarded advanced Immunology specialization courses at Scoular Superior d'Immunologia Ruggero Ceppellini, Italy. He served and continues to serve as a Research Scientific Consultant for Industry and higher education. His broad research interests include studies of new therapeutic approaches of chronic diseases by the use of Systems Medicine, through Systems Biology and Nutritional Systems Biology; Lipid Hemagglutinins, Lectins, Immunology and the use of novel interventions against Metastatic Tumor Cells. As from 2004.

Bio<mark>graphy</mark>

EuroSciCon &

Title: A p53-inducible IncRNA-H6 maintains genome integrity

Mian Wu University of Science and Technology of China China Dr. Mian Wu graduated from Nanjing Normal University in 1981 (BS), and obtained his PhD degree from Columbia University, USA in 1988. He then continuously conducted his postdoctoral research at Harvard University during 1988-1991. Thereafter, he moved to Singapore as an Assistant Professor at School of Biological Sciences of National University of Singapore. Started from 2000, he worked as a full professor at University of Science and Technology of China in Hefei, Anhui. His research interests focus on molecular mechanisms for p53regulated tumor development and regulation of non-coding RNA in tumor metabolism. He has published more than 60 research papers on international peer-reviewed journals with more than 2900 citations.

Title: Electrochemotherapy in locally advanced pancreatic cancer: preliminary results.

Francesco Izzo National Cancer Institute of Naples Italy Dr Izzo is Director and Chief of the Division of Abdominal Surgical Oncology (Hepatobiliary and Pancreatic Unit), within the Department of Surgical Oncology at the National Cancer Institute of Naples. His clinical practice and research focuses on new surgical oncology treatments and he has been a pioneer in designing improved techniques for surgical removal of hepatic tumours and direct tumour injection therapies. Additionally, Dr Izzo is Principal Investigator of a number of national and international protocols in this field and has authored or co-authored more than 220 publications and 18 book chapters relating to the treatment of patients with HPB tumours. He is an active member of numerous professional societies, including the European Society of Surgical Oncology, the World Federation of Surgical Oncology, Society of Surgical Oncology and the American Society of Clinical Oncology.

Title: Androgen receptor (AR) cistrome and Prostae Cancer Progression

Hari K Koul Louisiana State University USA Dr. Hari K Koul completed his PhD in Biochemistry at the Post Graduate Institute of Medical Education and Research (PGI), Chandigarh India and postdoctoral studies from University of Massachusetts Medical School, Worcester, MA. He is Follow of American Society of Nephrology, Fellow of American College of Nutrition and Overseas Fellow of the Royal Society of Medicine, England and immediate past President of The Society of Basic Urologic Research (SBUR)-USA. He has served as Professor at University of Colorado (2003-2013). He has published more than 60 papers in reputed journals and is the Professor, Carroll W. Feist Endowed Chair, Department of Biochemistry and Molecular Biology, and Director of Research at the Feist Weiller Cancer Center at Louisiana State University Health Sciences Center, Shreveport, LA, USA.

Bio<mark>graphy</mark>



Michele Gallucci National Cancer Institute of Rome Italy Dr. Gallucci has completed his Specialization in Urology at "Sapienza" University of Rome, Dept. of Urology. He is Director of the Department of Oncologic Urology at "Regina Elena" National Cancer Institute of Rome, since 2001. He has published more than 200 papers in reputed journals, most of them concerning the urological cancers. His main clinical activity is focused on the surgical treatment of urological malignancies.

EuroScilon &

Title: Acute Myeloid Leukemia with CEBPA, NPM1, RUNX1 Gene Mutations

Ryan S.Robetorye Mayo Clinics USA Dr. Ryan S. Robetorye received his M.D. and Ph.D. degrees from Baylor College of Medicine in Houston, Texas. He is board certified in Clinical Pathology, Hematology, and Molecular Genetic Pathology and currently works as a Consultant at the Mayo Clinic in Phoenix, Arizona. He currently serves as the Medical Director of the clinical laboratories at the Mayo Clinic. His research interests primarily involve hematological malignancies and molecular diagnostics involving gene expression profiling and next-generation sequencing.

Title: Personalized and Translational Medicine as a Model of the Healthcare Services and Armamentarium to get the Model Armed

Sergey Suchkov Moscow State University Sergey Suchkov was born in the City of Astrakhan, Russia, in a dynasty of medical doctors, graduated from Astrakhan State Medical University and was awarded with MD. Then maintained his PhD and Doctor's Degree. And later was working for Helmholtz Eye Research Institute and Moscow Regional Clinical Research Institute (MONIKI). Dr Suchkov was a Secretaryin-Chief of the Editorial Board, Biomedical Science, an international journal published jointly by the USSR Academy of Sciences and the Royal Society of Chemistry, UK. At present, Dr Sergey Suchkov is: (i) a Director, Center for Personalized Medicine, Sechenov University, (ii) Chair, Dept for Translational Medicine, Moscow Engineering Physical University (MAPhI), and (iii) Secretary General, United Cultural Convention (UCC), Cambridge, UK. A Member of the: New York Academy of Sciences, American Chemical Society (ACS), American Heart Association (AHA), AMEE, Dundee, UK; EPMA, Brussels, EU; PMC, Washington, DC, USA and ISPM, Tokyo, Japan.





Title: A novel cellular crosstalk promoting tumor progression and metastasis

Andrei V. Bakin Roswell Park Cancer Institute USA Dr. Andrei Bakin is currently Associate Professor in the Department of Cancer Genetics at Roswell Park Cancer Institute. Dr. Andrei Bakin has received a doctoral degree from Lomonosov University, Moscow. He was trained in cancer research with Dr. Tom Curran at St. Jude Children's Research Hospital, and in breast cancer with Dr. Carlos Arteaga at Vanderbilt University. Dr. Bakin has done pioneering studies on EMT in cancer progression. His group has identified novel therapeutic targets driving metastasis. He has mentored over ten graduate students. He is also a member of Editorial Board of scientific journals and active member of AACR.

Title: Pharyngoesophagic reconstruction in carcinomas of the hypopharynx or esophagus. Retrospective study of 81 cases.

Jose Francisco de Sales Chagas Sao Leopoldo Mandic medical school Brazil I'm 63 years old and I've been trained for 40 years in general surgery and head and neck surgery. Teaching residents since 1982 and I was professor and head of the head and neck surgery service of the medical school Catholic University in Campinas, Brazil for 23 years. I am currently director of the Sao Leopoldo Mandic medical school in the city of Araras, Brazil

Title: Tumour cell-specific death by non-death domain-containing TNF receptors

Nik T. Georgopoulos University of Huddersfield United Kingdom Nik received his BSc (Biochemistry & Genetics) and his Ph.D. at the University of Leeds. This was followed by a post-doctoral fellowship at the Cancer Research UK Centre (St James' Hospital, Leeds) and an EPSRC-funded fellowship in the Jack Birch Unit of Molecular Carcinogenesis (University of York). Following that he moved to the Department of Biological Sciences at the University of Huddersfield where he is currently a Reader (Associate Professor) in Cell Biology. Nik's research focuses on understanding how the process of epithelial cancer development influences proliferation/growth, differentiation and particularly cell responses to death signals triggered by members of the TNF Receptor (TNFR) family of proteins. The aim is to use such knowledge to design novel, tumour-specific anticancer therapies. Currently he is developing a novel platform of cancer therapeutics based on the TNFR family (ThanatoCure™). His skin-related research involves using biological models to explore, at the cellular and molecular level, the underlying mechanisms of defective wound healing and chemotherapy-induced alopecia. This will permit the improvement of existing medical devices and design of novel technologies to provide improved therapeutic intervention strategies. Nik has a major industrial collaboration on skin related research with Paxman (http://paxman-coolers.com).



Title: Physical activity in cancer survivor: a study in Italy.

Alice Avancini University of Verona Italy

Alice Avancini is a young doctor in Preventive and Adapted Exercise Science. She is a PhD student in Clinical and Experimental Biomedical Sciences in University of Verona. Her main interest regard the promotion on healthy lifestyle in healthy people and in persons with chronic disease, in particular in cancer survivors.

Title: Bridging the gap in health systems through task-sharing: a model of PHC workers' Competency for Cervical Screening

Irikefe Obiebi Delta State University Teaching Hospital Nigeria Dr. Irikefe Paul Obiebi completed his MD in Medicine at University of Benin (2008) and residency/ fellowship training in Community/Public Health in the West African College of Physicians (2016) and he is currently in pursuit of a PhD in Public Health from Texila American University and University of Central Nicaragua. He has worked as a Physician in Delta State Hospitals Management Board and works in Delta State University Teaching Hospital as a Public Health Specialist. His research interests include among others sexual and reproductive health with a strong bias for cancer prevention. He has published several papers in reputed journals and has many on-going research projects.

Title: Impact of Deploying A Genetic Approach to Stem Cells Opens-Up New Facets in the "Blank Slates" of Our Body

Jyoti Bhojwani Indore University India Dr. Jyoti Bhojwani, is presently a Faculty of Genetics/Bioinformatics/ Principal Investigator of the M.Tech Research Programs (Bio-Informatics) at University of Indore, India. She obtained her B.Sc. (Bachelor's degree) in Biological Sciences/Chemistry/Physics, M.Sc. (Master's degree) in Life-Sciences, and Doctoral degree (Ph.D.) at School of Life-Sciences, University Of Indore. She pursued her post-doctoral ventures at Max-Planck Institute For Biophysical Chemistry (FRG), University Of California-Irvine and University Of Pittsburgh (USA). Currently, her projects mainly focus on translational-research and extrapolation of basic developmental mechanisms from model-systems like fruitfly (Drosophila) to human. Apart from this, her thrust areas of research interest include; Cancer Biology, Stem-Cell Biology and Homeotic-Gene Regulation. She is keen on studying in details the genetic factors, which presumably aid in understanding of mechanism by which "cancer stem cells" function in transforming a tissue from normal to cancerous states.



Title: Cancer Survivorship in the first person: Nine years with Stage IV disease

Alan Lefore Jichi Medical University Japan Alan Kawarai Lefor is Professor of Surgery at Jichi Medical University in Tochigi, Japan where he specializes in surgical education. He received the MD degree from SUNY Upstate (1982), an MPH from UCLA (1999) and a PhD in theoretical astrophysics from Tohoku University (2015). He is the author of over 500 publications as well as 12 textbooks in English and Japanese.

Title: Outcome in Elderly patients with poor Performance status treated with High dose Hypofractionated Palliative radiotherapy for Stage II and III NSCLC Patients

Tarun Durga Southerland University United Kingdom Elderly patients (\Box 70 yrs.) with stage II & III NSCLC who were not candidates for surgery, radical radiotherapy or chemo-radiation due to diminished PS (PS 2 or greater) or large tumour volumes not amenable to be treated radically due to OAR toxicity were treated with High dose hypo-fractioned alone using a dose of 36-39 GY in 12-13 fractions over two and half week. Local control rates and Overall survival was the primary endpoint with several secondary endpoints including toxicity assessment, progression free survival (PFS), and quality of life. Chemotherapy was permissible in the adjuvant or palliative setting upon progression.

The study looked at patients treated with High dose palliative Radiotherapy in last 3 years

Results: 90 patients were eligible for analysis. The median age was 74.5 years with a M:F ratio of 5:4. 56 % of all lesions were adenocarcinoma with the rest being squamous cell carcinomas.

82 /90 patients presented with stage III disease, 8/ 90 with stage II. Kaplan-Meier analysis, median OS for the 78 patients evaluable was 10.5 months. This compares favourably with radical radiotherapy survival in other studies.

Median PFS was 8 months No grade 4 toxicities were attributed to radiation.





Title: Cost effectiveness analysis of Cetuximab Treatment of Locally Advanced Head and Neck Cancer

Abdalla abo taleb WHO Egypt Abdalla Abo talleb is one of the most profound experts in healthcare policy and regulations in the Middle East. His expertise extend from HTA & Reimbursement policies to regulatory and supply chain strategies in the public sector. He has been involved in the fields of health economics, outcomes research, and reimbursement policy within the healthcare industry for 15 years, with experience across the pharmaceutical, biologicals and vaccines. And now works for WHO as a project manager at health care reforming area. He has graduated in faculty of pharmacy then obtained a post-graduate in health economics followed by a PhD in Health Economics & Policy form York University. He also has a degree in Project management professional (PMP), Pharm. D certificate and a Master of business administration (MBA). In addition, being a committee member and project manager in a number of national projects in many countries including Germany. United Kingdom, Egypt, Algeria, Sudan, Russia and Poland, He is a very active researcher with tens of publication across different well recognized organizing including ISPOR, ESMO, ASCO, ECCO, iHEA. HTAI, and EAHE.

Melissa Joyner The University of Texas, USA

Adrian Senderowicz Cerulean Pharma, USA

Vincent Balaya University Paris Descartes, France

Xueqing Wang Beijing Jishuitan Hospital, China

Xudong Miao Zhejiang University, China

Michael R Olin University of Minnesota, USA

Raushan Kurmasheva University of Texas Health Science Center, USA

Norbert Graf Saarland University, Germany

Liqin Du Texas State University, USA

Ravi Radhakrishnan University of Pennsylvania, USA **William Jia** University of British Columbia, Canada

Qiaofei Liu Peking Union Medical College Hospital, China

Lidija Covic Tufts Medical Center, USA

Shahla Masood UF Health Breast Center, USA

Gaiane M. Rauch University of Texas Cancer Center, USA

Michael Thompson University of Wroclaw,Canada

Emmanuelle Charafe-Jauffret University of Mediterranée, France

Chang Gong Sun Yat-Sen University, China

Ragheed Al-Mufti The West of London Breast Cancer Network, UK

Maude Hébert University of Quebec in Trois-Rivieres, Canada **Chiung-Fang Chang** Far Eastern Memorial Hospita

Han-Heom Na Kangwon National University, South Korea

Jaecheong Lim Korea Atomic Energy Research Institute, South Korea

Darya Tsvirkun The Hebrew University of Jerusalem

Surangkana Sanmai Khon Kaen University

Katarina Jeremić Belgrade University School of Medicine

Hazan Ozyurt Lutfi Kirdar Kartal Education and Research Hospital

Kennedy Gonçalves Pacheco Vascular Surgeon and Phlebologist

Tevfik Guvenal Celal Bayar University School of Medicine

Vineet Talwar Rajiv Gandhi Cancer Institute and Research Centre

Christian G. Chaussy

University Regensburg,Germany , Germany

KN Leung Chinese University of Hong Kong, China

Gregory G. Passmore Augusta University, United States, USA

Jim Burgess Augusta University United States, United States

Zoya Vinokur New York City College of Technology, USA

Benedict Benigno Ovarian Cancer Institute, USA

Sang Y Lee Penn State Health Milton S. Hershey Medical Center, USA

Jan Lewin University of Texas MD Anderson Cancer Center, USA

Hiroshi Osawa Edogawa Hospital, Japan

Saad Kenderian Mayo Clinic,USA

Thomas Mehrling CEO Mundipharma EDO GmbH, Switzerland **Guan Chen** Medical College of Wisconsin USA

M.A. Nezami MD Pacific Medical Center of Hope, United States

Mouad Edderkaou Cedars-Sinai Medical Center, USA

Yiu-Lian Fong Johnson & Johnson Innovation, UK

Karl R Aigner Medias Klinikum GmbH & Co. KG

Alireza Heidari Professor, USA

MA Nezami President, USA

Sputova K University of Miami Miller School of Medicine, USA

Nematallah Mansour Université de Sherbrooke, Canada

Omer Kucuk Emory University, USA

Qun Lu East Carolina University, USA **Aleksandar Stefanović** Association of gynecologist and obstetricians of Serbia

Tommy Nai-Jen Chang Chang Gung Memorial Hospital

Hossam El Sokkary Alexandria university

Somashekhar S.P Manipal Hospital

Kannan Vaidyanathan Pushpagiri Institute of Medical Science & Research Center

Georgios Stamatakos National Technical University of Athens

Elizabeth Algar Hudson Institute of Medical Research, Australia

Ines Vasconcelos Berlin Oncological Center Kurfürstendamm, Germany

Nalini Kant Pati Australian National University, Australia

Nahla Ali Mobark King Fahad Medical City

Jessy S Deshane University of Alabama at Birmingham, USA

Giuseppe Leone Catholic University

David J. Bearss CEO Tolero Pharmaceuticals, USA

Jack Sariego Aria-Jefferson Health System, USA

Ashutosh Kothari Guvs Hospital, UK

Hong Zhang University of Texas-M D Anderson Cancer Center, USA

Yun Gong MD Anderson Cancer Center, USA

Sheldon Milstien Virginia Commonwealth University, USA

Senqing Chen Jiangsu Institute of Cancer Research, China

Julia Gerasimenko Cardiff University, UK

Feng Yan Nanjing Medical university Hospital, China

Andreas Lehmann Fraunhofer Institute for Ceramic Technologies and Systems **Taisei Nomura** Osaka University, Japan

Jennifer L Young The Urology Group, USA

Lucia R Languino Thomas Jefferson University, USA

Jiao Zhang East Carolina University, USA

Aejaz Sayeed Thomas Jefferson University, USA

Kristina Shahriari Drexel University, USA

Zhi Ping Xu University of Queensland, Australia

David K. Imagawa University of California, USA

Rupinder Kaur Deakin University, Australia

Veronica J James Australian National University, Australia

Pascal H G Duijf University of Queensland, Australia **Ines Vasconcelos** Berlin Oncological Center Kurfürstendamm, Germany

Michael G Hanna Vaccinogen Inc., USA

María del Rosario Dávalos Gamboa University of San Simón

Ines Vasconcelos Berlin Oncological Center Kurfürstendamm, Germany

Alex Agyekum Bikbok Herbal Centre

María Marcela Barrio Centro de Investigaciones Oncológicas Fundación Cáncer

Petrousjka van den Tol VU University Medical Center

Marco Bernini Careggi University Hospital

Baek Kwang-In The institute of Koryo Acupotomology, Korea

Larysa M.Skivka Professor, Ukraine

Waleed Seif El-Din Mohamed Mostafa Professor Cairo University

Juan F Roman Cambridge Consultants Medical Technology, UK

Oleg Gerasimenko Cardiff University, UK

Julia Gerasimenko Cardiff University, UK

Jessy Deshane University of Alabama at Birmingham, USA

Andreas Lehmann Fraunhofer Institute for Ceramic Technologies and Systems

Jennifer Wu Hollings Cancer Centre, USA

Peter Weightman University of Liverpool, UK

Alok De Kansas City Vet Center, USA

Jeffrey B Ulmer Novartis Vaccines & Diagnostics, USA

Michael Goris Stanford University School of Medicine, USA

Shuo Li GE Healthcare, Canada **Jagat R Kanwar** Deakin University, Australia

Susan J Done University of Toronto, Canada

Igor Buchwalow University of Muenster, Germany

Thomas Kieber-Emmons University of Arkansas for Medical Science, USA

Stefan B. Eichmüller German Cancer Research Center, Germany

Raj Tiwari New York Medical College, USA

Alex Dommann Swiss Federal Laboratories for Materials Science and Technology,

Niccola Funel University of Pisa

Wassil Nowicky Ukrainian Anti-Cancer Institute

Francesco Zinno University of Rome Tor Vergata

Jan Jacques Michiels Goodheart Institute Mohamed EL-Far Professor, Egypt

Bogusław Maciejewski Director, Poland

David Huang Professor, China

Nina Tuncel Professor, Turkey

Bahram Mofid Shahid Beheshti University of Medical Sciences

Sheeba Jacob Mumbai University

Fahri Saatcioglu Oslo University Hospital

Elif Damla Istanbul Kultur University

Guldeniz Karadeniz Cakmak Bulent Ecevit University

Diptendra K Sarkar Professor, IPGMER

Sadir Jumaa Alrawi Tawam Cancer Centre

Leung KN The Chinese University of Hong Kong, China

Morio Sato Wakayama Medical University, Japan

IkuoTooyama Shiga University of Medica Science, Japan

Doungdean Tummanatsakun Khon Kaen University

Kuo-Wang Tsai Kaohsiung Veterans General Hospital

Shahram Bahmanyar Karolinska Institutet Stockholm, Sweden **Shikai Wu** Academy of Military Medical Sciences, China

Shahram Bahmanyar Karolinska Institutet Stockholm, Sweden

Cohen-Armon Tel-Aviv University

Anne Ryhänen University of Turku

Hsu-Shan Huang Taipei Medical University

Syed Rahmanuddin Radiology Center City of Hope, USA Deepak Kaul


Postgraduate Institute of Medical Education & Research, India

Fritz Lahrtz Isenbruck Bösl Hörschler LLP Prinzregentenstr, Germany

Yaffa Mizrachi Nebenzahl Ben Gurion University of the Negev

Mahmoud El-Foudeh King Faisal Specialist Hospital & Research Center, Saudi Arabia

Giulio Tarro Foundation de Beaumont Bonelli for Cancer Research, Italy



Plan A Trip To Moscow: Destination Of Cancer Survivorship 2018

Moscow is the capital and over crowed city of Russia, with 13.2 million residents at the city limits, and 17.1 million at urban area. Moscow has the position of a Russian federal city. By broader Moscow is one of the largest cities around the world. It is being the 14th largest metro area in the world. It is the 18th largest agglomeration in the world, the 15th largest urban area. According to Forbes 2013, Moscow has given the ninth rank in the world. Moscow is present on the Moskva River in the Central Federal District of European Russia, that being makes it Europe's most densely populated inland city. The city includes strength of architecture, especially its historic buildings includes Saint Basil's Cathedral with its brightly colored domes. Moreover 40 per cent of its territory covered by greenery and it is one of the greenest capitals and important cities in Europe and the world. It is having the vast dense forest in an urban area within its borders more than any other major city. The city has aided as the capital of a progression of states, from the medieval Grand Duchy of Moscow and the following. Moscow has integrity among foremost political, economic, scientific center of Russia

Explore This Embodiment Tourist Heritage

Moscow, a city which comprises both modern architecture and historical monuments is a place worth visiting once in a lifetime. Following are the famous tourist marvels of the city





City Attractions





